secwatch.observer — SEC 8-K summary
======================================

Issuer:     OCULAR THERAPEUTIX, INC (OCUL)
CIK:        0001393434
Form:       8-K
Filed at:   2023-07-12T23:59:59+00:00
Accession:  0001104659-23-080180
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Ocular Therapeutix elects Adrienne L. Graves, Ph.D. to board effective July 10, 2023
--------------------------------------------------------------------------------

- Dr. Graves elected as Class I director, term until 2024 annual meeting.
- Former President & CEO of Santen Inc. (US subsidiary of Japanese pharma).
- Receives option to purchase 72,000 shares at $5.04/share and RSU for 24,000 shares.
- Standard indemnification agreement entered upon election.
- No material arrangements or transactions requiring disclosure under Item 404(a).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1393434/000110465923080180/0001104659-23-080180-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1393434/000110465923080180/tm2321078d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-080180

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer